SMARCA4-mutated patients had worse CIT treatment outcomes than SMARCA4 WT patients in both KRAS WT and KRAS-mutated non-squamous NSCLC [22]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.